Watson-Actavis talks confirmed: merging geography and biosimilars
This article was originally published in Scrip
Executive Summary
It has been confirmed to Scrip by sources very close to the company that two of the world's leading generic medicines companies are negotiating a merger to create a company with generic drug sales approaching €6 billion. While the official line from both companies was no comment', various sources confirmed that a negotiation was taking place, that matters were close to being finalised, and that the expectation was that a deal would be concluded in the next few weeks.